IL-5 Production by Donor and Recipient Derived ILC2.

(A) IL-5 production, defined as relative IL-5 MFI or % IL-5+ in donor vs. recipient-derived ILC2s of Balb/c^CD45.2+ to B6^CD45.1+ lung transplants (left side of graphs) vs. resting non-transplanted Balb/c^CD45.2+ and B6^CD45.1+ lungs (right side of graphs). Relative MFI of 1 was set as level defined by B6^CD45.2+ ILC2 from resting non-transplanted lungs which were run with every experiment as an internal control. Tissue was collected and analyzed at post-engraftment day 4. (B) Relative ratio of donor vs. recipient-derived ILC2s in grafts of Balb/c^CD45.2+ to B6^CD45.1+ lung transplants on day 1,4,7,14 and 21 days post-engraftment. Graft recipients were treated with CSB immunosuppression. (C) Relative percentage of intraparenchymal vs. intravascular donor and recipient-derived ILC2s in Balb/c^CD45.2+to B6^CD45.1+ lung grafts as identified by flow cytometry. (D) Relative alteration in IL-5 expression in donor vs recipient-derived ILC2s in Balb/c^CD45.2+ to B6^CD45.1+ lung grafts on day 1,4,7,14 and 21 days post-engraftment. Data representative of three separate experiments. CSB=co-stimulatory blockade; MFI = Mean fluorescent intensity (geometric mean). ns=p>0.05; * =p<0.05; ***=p<.001